Navigation Links
Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
Date:11/21/2007

microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. An NDA filing is expected to take place in the second half of 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed three Phase I trials: an ADME study (absorption, distribution, metabolism and excretion) with radiolabelled compound, a Phase I bioavailability trial with a solution and one with a capsule formulation. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An ad
'/>"/>

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Blood Donations in U.S. Testing Positive for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Shimadzu Corporation announced that its fully ... (Nexera UC) received the Pittcon Editors’ Gold award ... and Applied Spectroscopy (Pittcon) held in New Orleans, ... The Pittcon Editors’ Awards recognize the most innovative ... based on votes by the media corps. Editors ...
(Date:4/1/2015)... -- ValGenesis Inc., the market leader in enterprise Validation Lifecycle ... its Service Organization Controls 2 (SOC 2) examination under ... the period of January 1 st  2014  through ... Logo - http://photos.prnewswire.com/prnh/20150401/195954LOGO ... The SOC 2 examination is performed in accordance with ...
(Date:4/1/2015)... 2015 Proove Biosciences , a ... presented two scientific posters at the Annual Clinical Genetics ... four-day event was hosted at the Salt Palace Convention ... educating genetic and genomic professionals on breakthrough advances in ... Study on the Role of DAT1 in Risk of ...
(Date:4/1/2015)... April 1, 2015  Organovo Holdings, Inc. (NYSE ... on delivering breakthrough 3D bioprinting technology, presented data ... at the 2015 Experimental Biology conference in ... "Kidney represents an ideal extension of Organovo,s capabilities ... tremendously useful in pharmaceutical research," said Keith ...
Breaking Biology Technology:Shimadzu Nexera UC Recognized at Pittcon 2015 with Editors’ Gold Award 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 3Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 4
... MEDFORD/SOMERVILLE, Mass. -- Promising research on superconducting materials, near ... Tufts University,s School of Engineering early career awards from ... The awards are among the most prestigious honors given ... at the early stages of their careers, when many ...
... March 23 The Superior Court of Pennsylvania has reinstated an appeal filed by ... been dismissed by an order from the same court on February 18, 2010 . The Superior Court also ... ... , ...
... - and authorities on the track of illicit alcohol ... hand. Measurement experts have unveiled a portable device to ... almost anywhere. Published in the open access Chemistry ... is just as accurate, and more sophisticated, than widely ...
Cached Biology Technology:3 Tufts engineering faculty earn prestigious national awards for promising research 23 Tufts engineering faculty earn prestigious national awards for promising research 3UPDATE: Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated 2How strong is your booze? 2
(Date:3/18/2015)... March 18, 2015 As mobile payments ... revolutionary smart wallets and apps continue to be introduced into ... in the mobile payment industry in focus today are:  NXT-ID, ... (NYSE: BABA ), Apple Inc. (NASDAQ: ... Facebook Inc. (NASDAQ: FB ) NXT-ID, ...
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... March 12, 2015 WHEN:Tuesday, March 17, 2015 ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must ... in several different markets and industries. This is ... an uptrend. Join Frost & ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... RIVERSIDE, Calif. ( www.ucr.edu ) -- A team led ... Bourns College of Engineering has made a discovery in ... from kill viruses to increase storage capacity of DVDs. ... data processing, information storage and biology. Their applications have ...
... 19th conference of the International Society for Sexually Transmitted ... in Quebec City, Canada. The world,s foremost conference ... 1,200 scientists from every continent to discuss the most ... and treatment; emerging threats in bacterial STDs; major intervention ...
... Spanish . The last of seven cotton ... a major 4-year cotton gin dust sampling project draws to ... project to intensively sample emissions from seven cotton gins across ... Research Service (ARS) Cotton Production and Processing Research Unit in ...
Cached Biology News:New laser technology could kill viruses and improve DVDs 2ARS and cooperators study cotton gin dust emissions 2
... Anti-M13 polyclonal antibody was derived from rabbit ... particles.Recombinant protein domains such as antibody fragments ... pIII and displayed on phage using phagemid-based ... utilized in the Ph.D. libraries. Anti-M13 pIII ...
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
Biology Products: